Understanding a family of human enzymes that affect how drugs and fats are processed
Official title: Structure-Function Studies of the Human Cytochrome P450 27 Family
Funded at Appalachian State University · NIH-11352591 · Data updated 2026-11-12
A study at Appalachian State University looks at how a specific group of human enzymes (P450 27 family) shape the body’s use of medicines, fats, and hormones, with potential to lead to safer therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Appalachian State University NIH-funded |
| Lab location | 1 site (Boone, United States) |
| Project start | September 5, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $345,000 |
| NIH project number | 5R35GM147276-05 |
| Project ID | NIH-11352591 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients affected by conditions related to cholesterol, hormone metabolism, or vitamin D pathways who may benefit from future therapies targeting P450 enzymes.
✕Less likely to help
Individuals with conditions unlikely to involve P450 27 enzymes or who would not participate in future translational steps may see no direct benefit.
What this research studies
This project investigates how the structure of the P450 27 family enzymes interacts with a partner protein to influence enzyme function. Researchers aim to map how these interactions change the enzymes’ shapes and activities, which could guide the design of targeted treatments. The work focuses on uncovering mechanisms that could enable more selective drug strategies and safer hormone and vitamin processing. Results could help future therapies that better manage cholesterol, vitamin D derivatives, and retinoids while reducing side effects. The study is scientifically focused but tied to mechanisms that could translate into clinical advances down the line.
Why it matters
Potential benefit: If successful, the research could inform the development of safer, more precise therapies that modulate specific enzyme activities involved in drug metabolism and disease-related processes.
How similar studies have gone: Previous work on cytochrome P450 enzymes has led to safer drug use and new therapeutic approaches, though the P450 27 family remains less explored.
Where this research is happening
-
Appalachian State University
Boone, United States Active
Researchers
- Principal investigator: Reddish, Michael Jerrell — Appalachian State University
- Study coordinator: Reddish, Michael Jerrell
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.